<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739397</url>
  </required_header>
  <id_info>
    <org_study_id>EG-001</org_study_id>
    <nct_id>NCT04739397</nct_id>
  </id_info>
  <brief_title>Evaluation of the EpiGlare Tester for the Measurement of Glare-Induced Changes in BSCVA in Subjects With and Without Cataracts</brief_title>
  <official_title>Evaluation of the EpiGlare Tester for the Measurement of Glare-Induced Changes in BSCVA in Subjects With and Without Cataracts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epico, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epico, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EpiGlare Tester will identify visual disability resulting from the glare experienced by&#xD;
      subjects with cataracts in the glare-induced change in best spectacle corrected visual acuity&#xD;
      (BSCVA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:&#xD;
&#xD;
        1. Are 18 years of age or older.&#xD;
&#xD;
        2. Have been evaluated by an opthalmologist and have a lens determination of either Normal&#xD;
           or Cataract in each eye based on slit lamp examination.&#xD;
&#xD;
             1. Normal = lens opacity of clear or trace&#xD;
&#xD;
             2. Cataract = lens opacity of 2+ or greater&#xD;
&#xD;
        3. Have written informed consent as required by the site's IRB and received a copy.&#xD;
&#xD;
        4. Are willing and able to comply with testing according to the Investigator.&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        1. Best corrected visual acuity is worse than 20/60 in either eye&#xD;
&#xD;
        2. Have occular pathology including corneal or macular disease or advanced glaucoma&#xD;
&#xD;
        3. Have cognitive dysfunction which limits the ability to cooperate with testing.&#xD;
&#xD;
        4. Have presence or history of any other condition or finding or concomitant medication&#xD;
           that, in the investigator's opinion, makes the subject unsuitable as a candidate for&#xD;
           EpiGlare or study participation or may confound the outcome of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in best spectacle corrected visual acuity (BSCVA) measurements before and after glare testing using the EpiGlare Tester as the glare source.</measure>
    <time_frame>up to 16 months</time_frame>
    <description>Change in best spectacle corrected visual acuity (BSCVA) measurements before and after glare testing using the EpiGlare Tester as the glare source in patients with and without cataracts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of functional visual ability using driving and glare subscales from the Refractive Status Vision Profile (RSVP) questionnaire</measure>
    <time_frame>up to 16 months</time_frame>
    <description>Correlation of the EpiGlare Tester's glare-induced changes in BSCVA with functional glare disability, as measured by the glare subcategory from the RSVP questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>User's assessment using a subjective questionnaire.</measure>
    <time_frame>up to 16 months</time_frame>
    <description>Users evaluated the device using a subjective questionnair</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">89</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Cataract</arm_group_label>
    <description>Patients with bilateral cataracts with Lens grade 2+ or greater, cataract classification nuclear, cortical or posterior subcapsular</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Cataract</arm_group_label>
    <description>patients with bilateral clear lenses (no cataracts)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glare Testing</intervention_name>
    <description>Vision in Cataract patients were tested with and without the EpiGlare Tester</description>
    <arm_group_label>Cataract</arm_group_label>
    <arm_group_label>Non-Cataract</arm_group_label>
    <other_name>EpiGlare Tester</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Candidates were identified from the investigator's usual clinic population. Subjects&#xD;
        presenting to the investigators clinic were examined according to the usual procedures.&#xD;
        Subjects were classified as having either bilateral cataracts or clear lenses in both eyes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        clear lenses OU cataracts OU willing to comply with testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        BCVA &lt; 20/63 either eye ocular pathology (ie corneal, macular disease, advanced glaucoma)&#xD;
        cognitive dysfunction other conditions that in the investigators opinion made the subject&#xD;
        unsuitable candidate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole R Fram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Vision Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Masket, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Vision Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fancis W Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Doyle Stulting, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woolfson Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Eye Center of Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Epitropoulos AT, Fram NR, Masket S, Price FW Jr, Snyder ME, Stulting RD. Evaluation of a New Controlled Point Source LED Glare Tester for Disability Glare Detection in Participants With and Without Cataracts. J Refract Surg. 2015 Mar;31(3):196-201. doi: 10.3928/1081597X-20150225-03.</citation>
    <PMID>25751837</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Disability glare</keyword>
  <keyword>contrast sensitivity</keyword>
  <keyword>cataract</keyword>
  <keyword>method evaluation</keyword>
  <keyword>glare test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

